🇺🇸 FDA
Pipeline program

BI 456906

1404-0002

Phase 2 small_molecule completed

Quick answer

BI 456906 for Diabetes Mellitus, Type 2 is a Phase 2 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Diabetes Mellitus, Type 2
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials